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ABSTRACT   Chronic inflammation plays a key role in the pathogenesis of malignant pleural 
mesothelioma as a result of asbestos exposure. Signal transducer and activator of transcription 
3 (STAT3) signaling is a major pathway for cancer inflammation. The purpose of this study was 
to investigate the effectiveness of a new STAT3 inhibitor, BBI608, on mesothelioma cells in 
vitro  and in vivo . The results showed that BBI608 blocked STAT3 phosphorylation, with and 
without suppression of IL-6. The effects of BBI608 on STAT3 downstream target genes such 
as cyclin D1 and survivin involved a decrease in cell viability with induction of apoptosis and 
cell cycle arrest. Nuclear translocation of phosphorylated STAT3 was blocked by BBI608. In 
addition, the agent showed significant antitumor activity in xenograft mouse models implanted 
with mesothelioma cells. These findings suggest that BBI608 may be a novel agent for 
malignant mesothelioma. doi：10.11482/KMJ-E201945061　(Accepted on July 16, 2019)
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〈Regular Article〉
INTRODUCTION
   Malignant pleural mesothelioma (MPM) is a rare 
malignant tumor arising from mesothelial cells 
of the pleura. It accounts for less than 0.3% of all 
cancers１）. It is generally accepted that asbestos 
exposure is responsible for MPM carcinogenesis２）. 
Although asbestos has been banned in most 
industrialized countries, the highest incidence of 
MPM is expected to occur in the coming decades 
because of the long latency between exposure and 
diagnosis１）. Most patients present with unresectable 
disease at diagnosis or are deemed inoperable due 
to age or medical comorbidities. Although several 
treatment options have been introduced３）, the 
median survival time is approximately 12 months４）. 
The standard first-line treatment for advanced 
MPM, cisplatin plus pemetrexed chemotherapy, has 
a short and insufficient efficacy５）, and no validated 
treatment beyond first-line therapy is available. 
Novel therapeutic strategies are therefore needed.
   Systemic inflammatory responses play an 
important role in cancer progression６）, and chronic 
inflammation contributes to almost every aspect of 
tumor development７）. Although the mechanisms 
of MPM carcinogenesis are not completely 
understood, chronic inflammation is involved in 
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   Inhibitors of STAT3 signaling can be divided into 
agents that act either directly or indirectly19）. Several 
compounds, including Stattic (6-Nitrobenzo[b]
thiophene-1,1-dioxide), BBI608 (napabucasin), 
and STA-21 inhibit STAT3 by directly binding to 
the protein20－22）. Indirect inhibition of STAT3 can 
be achieved by interrupting the kinases upstream 
of STAT3 signaling using JSI-124 (cucurbitacin 
I), which is a small molecule inhibitor that targets 
the JAK/STAT3 pathway23）. Although the role of 
STAT3 signaling in mesothelioma cell lines is still 
unknown, this pathway may represent an attractive 
therapeutic target. Thus, it is important to determine 
the role of STAT3 activation in mesothelioma 
cells. In this study, we determined the antitumor 
activities of a new STAT3 inhibitor, BBI608, on 
mesothelioma cells in vitro and in vivo.
MATERIALS AND METHODS 
1. Cell lines and culture conditions
   Four human mesothelioma cell lines (MESO-1, 
H2452, H28, and MSTO-211H) were purchased 
from the American Type Culture Collection 
(Manassas, VA, USA). All cells were grown in 
Roswell Park Memorial Institute (RPMI)-1640 
medium supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) and 1% penicillin–
streptomycin. The cells were incubated in a 
humidified 5% CO2 environment at 37℃.
2. Agent
   BBI608 was purchased from Selleck Chemicals 
(Houston, TX, USA). Stock solutions of the agent (1 
mM) prepared in dimethyl sulfoxide (DMSO) were 
stored at －20℃
3. Cell viability assay
   Cells (3,000-4,000 cells/well) were seeded into 
96-well plates and continuously exposed to each 
drug for 72 h. Cell viability was measured using the 
modified 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl 
the pathogenesis of MPM as a result of asbestos 
exposure８）. Consistent with this possibility, we 
previously reported that inflammation-based scores 
such as the lymphocyte-to-monocyte ratio are useful 
for prognostic prediction in MPM patients９）.
   Signal transducer and activator of transcription 
3 (STAT3) is a transcription factor that is activated 
in response to extracellular cytokines such as 
interleukin-6 (IL-6) and growth factors. STAT3 
is considered an oncogene and is constitutively 
activated in many types of human malignancies10）. 
STAT3 activation occurs when the Tyr705 residue 
is phosphorylated, leading to dimerization and 
translocation of STAT3 from the cytoplasm to the 
nucleus11）. In the nucleus, STAT3 binding to target 
genes induces the transcription and upregulation 
of proteins associated with proliferation and 
anti-apoptosis. Abnormally activated STAT3 
signaling is involved in stimulating cell cycle 
progression and preventing apoptosis, both of 
which contribute to malignant progression12）; as 
a result, STAT3 signaling is a major pathway for 
cancer inflammation13）. One of the cytokines that 
induces STAT3 phosphorylation via Janus kinase 
(JAK) phosphorylation is IL-6. Increasing evidence 
has shown that tumorigenesis caused by STAT3 
is mediated by IL-6 signaling14）. Constitutively 
activated STAT3 has been described in human 
mesothelioma cell lines15）. In vivo experiments 
showed that high levels of IL-6 in the pleural fluid 
are detected in MPM patients16）. IL-6 promotes 
growth of mesothelioma cell lines via the STAT3 
signaling pathway in vitro17）. Furthermore, studies 
using butein (3,4,2',4'-tetrahydroxychalcone), a 
naturally occurring and dual nuclear factor kappa B 
and STAT3 inhibitor, have shown that the antitumor 
effect on mesothelioma cells involves inhibition of 
phosphorylated STAT318）. These reports indicate 
that STAT3 is one of the major oncogenic pathways 
activated in mesothelioma cells, implicating STAT3 
as a viable therapeutic target.
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tetrasolium bromide (MTT) assay24）. IC50 was 
defined as the concentration resulting in a 50% 
reduction in growth compared with the control cell 
growth.
 
4. Western blot analysis and antibodies
   Mesothelioma cells were treated with different 
concentrations of DMSO (control) or BBI608 
for 4 h and then harvested. For IL-6 stimulation 
experiments, the cells were serum-starved for 24 h 
and pretreated with DMSO (control) or BBI608 for 
4 h. Then, 40-60 ng/mL recombinant human IL-6 
(Abcam, Cambridge, MA, USA) was added, and 
the cells were collected 30 min later. The collected 
cells were washed with cold phosphate-buffered 
saline (PBS) and lysed in ice-cold Mammalian 
Protein Extraction Reagent lysis buffer (Thermo 
Fisher Scientific, Waltham, MA, USA) containing 
protease and phosphatase inhibitors (Thermo 
Fisher Scientific). Cell lysates were clarified 
by centrifugation (14,000 rpm for 20 min), and 
the protein concentrations were determined by 
BCA protein assay (Thermo Fisher Scientific). 
Whole cell extracts were resolved using SDS-
PAGE, transferred to nitrocellulose membranes 
(GE Healthcare, Chicago, IL, USA), blocked 
with 5% nonfat milk, and probed with primary 
antibodies overnight at 4℃. Antibodies targeting 
phosphorylated STAT3 (Tyr705), STAT3, cyclin 
D1, PARP, Bcl-xL, survivin, and glyceraldehyde-
3-phosphate dehydrogenase were purchased from 
Cell Signaling Technology (Danvers, MA, USA). 
Membranes were then probed with horseradish 
peroxidase (HRP)-conjugated secondary antibodies 
(Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) and visualized using enhanced 
chemiluminescence reagent (GE Healthcare).
5. Cell cycle and apoptosis assays using flow 
cytometry
   Cells were seeded in a 6-well plate and treated 
with DMSO (control) or BBI608 for 24 h. After 
removing the culture medium, the cells were 
harvested and washed with PBS. For cell cycle 
detection, the cells were resuspended in PBS 
containing 0.2% Triton X-100 and 1 mg/mL RNase 
in the dark and stained with 50 μg/mL propidium 
iodide (PI). For the apoptosis assay, apoptotic 
cells were monitored using the annexin V–FITC/
PI apoptosis detection kit (Nacalai Tesque, Kyoto, 
Japan) and the MEBSTAIN Apoptosis TUNEL Kit 
Direct (Medical & Biological Laboratories, Nagoya, 
Japan) according to the manufacture’s protocols. 
Flow cytometric analyses were performed using the 
FACSVerse instrument (BD Biosciences, San Jose, 
CA, USA).
6. Enzyme-linked immunosorbent assay for IL-6
   Cells were seeded in six-well plates in RPMI 
1640 containing 10% FBS for 24 h and then were 
washed with PBS and cultured for an additional 24 
h in serum-free medium. To examine the effect of 
BBI608 on IL-6 secretion, the cells were treated 
with either DMSO (control) or BBI608 for 4 h in 
serum-free medium, followed by collection of the 
medium. The levels of IL-6 in the supernatants were 
analyzed by enzyme-linked immunosorbent assay 
(ELISA) using a human IL-6 ELISA Ready-SET-
GO kit (Thermo Fisher Scientific) according to the 
manufacturer’s protocols.
7.  Immunof luorescence analys is  o f  STAT3 
localization
   Cells were seeded on glass coverslips in six-
well plates. The next day, the cells were cultured 
in serum-free medium for 24 h and pretreated 
with BBI608 for 4 h, followed by induction with 
IL-6 for 30 min. The cells were then fixed with 
paraformaldehyde, permeabilized with methanol, 
blocked with PBS containing 0.3% Triton X-100 
and 1% bovine serum albumin (BSA), and then 
incubated with the anti- phosphorylated STAT3 
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antibody (1:100 dilution) overnight at 4℃. The cells 
were probed with Alexa 594-conjugated goat anti-
rabbit secondary antibody (1:200 dilution, Abcam) 
in the dark at room temperature for 1 h. Cell nuclei 
were stained with 4', 6'-diamino-2-phenylindole, 
and the coverslips were mounted using Vectashield 
m o u n t i n g  m e d i u m  ( Ve c t o r  L a b o r a t o r i e s , 
Burlingame, CA, USA). Images were captured 
using the Nikon Eclipse 600 microscope and NIS-
Elements D30 software (Nikon, Tokyo, Japan).
8. Immunohistochemical staining
   Immunohistochemical (IHC) staining was 
performed on 4-μm-thick sections of formalin-
fixed, paraffin-embedded tumor tissues. Sections 
were deparaffinized using a series of xylene, 
graded ethanol, and water immersion steps. After 
microwave antigen retrieval using Dako Target 
Retrieval Solution (Agilent, Santa Clara, CA, USA), 
the sections were incubated with 3% hydrogen 
peroxide to block endogenous peroxidase activity. 
The slides were blocked with 5% BSA and then 
incubated with antibodies against Ki-67 (1:400 
dilution, Abcam) and phosphorylated STAT3 (1:100 
dilution) overnight at 4℃, followed by incubation 
with HRP-conjugated secondary antibodies 
(Agilent). The slides were visualized using 3, 
3-diaminobenzidin (Agilent) and counterstained 
with hematoxylin. Apoptosis in the tumor specimens 
of the mouse model was examined by terminal 
deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay using the MEBSTAIN 
Apoptosis TUNEL Kit Direct according to the 
manufacture's protocol. Images of apoptotic cells in 
the sections were captured using the Nikon Eclipse 
600 fluorescent microscope. The percentage of 
positive cells was determined by counting at least 
1,000 cells from multiple randomly selected areas 
under identical conditions.
9. Mouse xenograft tumor model
   The experimental protocol was approved 
by the Ethics Review Committee for Animal 
Experimentation of Kawasaki University Graduate 
School of Medicine (Ethics Committee reference 
number: 17-072). H28  (6×106 cells/mouse) 
and MSTO-211H (4×106 cells/mouse) were 
injected subcutaneously into the right flank area 
of 6-7-week-old female BALB/cAJcl-nu/nu mice, 
which were purchased from CLEA Japan (Tokyo, 
Japan). After the tumors reached 100-150 mm3 
in size, ten mice were randomly allocated to the 
following PBS as the vehicle control once daily 
or BBI608 (40 mg/kg once daily). Each treatment 
was administered via intraperitoneal injection 
for 21 days. Tumor growth was determined by 
measuring the length (L) and width (W) of the 
tumors three times a week using calipers, and the 
tumor volume (mm3) was calculated as 0.5×W2×
L. After the mice were sacrificed, the tumors were 
harvested, snap-frozen in liquid nitrogen, and stored 
at -80℃. Part of the tumor tissues were fixed in 4% 
paraformaldehyde and embedded in paraffin. The 
levels of phosphorylated STAT3 and Ki-67 were 
examined by IHC staining. The TUNEL assay was 
used to detect the percentage of apoptotic cells in 
the xenograft tumors.
10. Statistical analysis
   All data are expressed as the mean ± standard 
error of the mean (SEM). All experiments were 
performed three times, and statistical significance 
was determined using the paired two-tailed 
Student’s t-test. A value of P < 0.05 was considered 
to indicate significance. *P < 0.05; **P < 0.01.
RESULTS
1. BBI608 suppressed the growth of mesothelioma 
cell lines.
   STAT3  ac t iva t ion  i s  impor tan t  for  ce l l 
proliferation and survival. We first evaluated the 
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cytotoxic effect of BBI608 in mesothelioma cell 
lines using the MTT assay. Treatment with BBI608 
for 72 h resulted in a dramatic decrease in cell 
viability in a dose-dependent manner (Fig. 1). The 
IC50 values (μM; mean± SEM) from three separate 
experiments were 0.40 ± 0.01 for MESO-1, 0.37 
± 0.02 for H2452, 0.36 ± 0.01 for H28, and 1.24 
± 0.05 for MSTO-211H.
2. BBI608 induced cell cycle arrest.
   To determine whether BBI608-mediated growth 
suppression was mediated by induction of cell 
cycle arrest or apoptosis, we performed cell cycle 
analysis. It was reported previously that the growth 
inhibitory effects of BBI608 are mediated by cell 
cycle arrest at the G0/G1 phase25）. Mesothelioma 
cells were treated with increasing concentrations 
of BBI608 for 24 h, and the percentages of cells in 
different phases of the cell cycle were determined. 
The distributions of cells in each phase are shown in 
Fig. 2. Treatment with BBI608 resulted in cell cycle 
Fig. 1. BBI608 suppressed the viability of mesothelioma 
cells.
Mesothelioma cells (MESO-1, H2452, H28, and MSTO-
211H) were treated with BBI608  at serially diluted 
concentrations for 72 h. Cell viability was analyzed by MTT 
assay.
Fig. 2. BBI608 induced cell cycle arrest.
Mesothelioma cells were incubated with the indicated doses of BBI608 for 24 h. The cell cycle was assessed 
using propidium iodide staining and flow cytometry. Treatment with BBI608 resulted in cell cycle arrest in 
the G0/G1 phase in MESO-1 and H2452 cells and in the sub-G1 phase in H28 and MSTO-211H cells. The 
percentages of cells in each phase were counted, and the cumulative data from three independent experiments 
are expressed as means ± SEM.
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arrest at the G0/G1 phase in MESO-1 and H2452 
cells and in increased percentages of sub-G1 phase 
in H28 and MSTO-211H cells.
3. BBI608 induced apoptosis.
   To evaluate the apoptosis-inducing effect of 
BBI608 in mesothelioma cells, the cells were 
treated with the inhibitors for 24 h, stained with 
annexin V-fluorescein isothiocyanate (FITC)/PI, and 
subjected to the TUNEL assay. The apoptotic cells 
were evaluated by flow cytometry, which showed 
that treatment with BBI608 induced apoptosis 
in a dose-dependent manner (Fig. 3A). We also 
confirmed apoptosis by TUNEL staining. As shown 
in Fig. 3B, treatment with 10 μM BBI608 for 24 h 
significantly increased the percentages of TUNEL-
positive cells compared with the untreated control 
cells.
Fig. 3. BBI608 induced apoptosis.
Mesothelioma cells were treated with BBI608 for 24 h and apoptotic cells were identified by annexin V–FITC/PI and TUNEL 
staining using flow cytometry. (A) Annexin V–FITC/PI staining showed that treatment with BBI608 induced apoptosis in a dose-
dependent manner. The early and late apoptotic cells are shown in the lower and upper right quadrants, respectively. (B) The 
TUNEL assay showed significantly increased apoptosis in the groups treated with 10 μM BBI608 for 24 h. The percentages of 
apoptotic cells after BBI608 treatment were counted, and the cumulative data from three independent experiments are expressed 
as means ± SEM. **P < 0.01 compared with the control group.
4. BBI608 suppressed STAT3 phosphorylation with 
the related proteins.
   Abnormally activated STAT3 has been implicated 
in the development of various human cancers. 
STAT3 activation relies on the phosphorylation at 
Tyr705, and this phosphorylation event induces 
its dimerization, nuclear translocation, and DNA 
binding12）. We first examined whether BBI608 
suppresses constitutive STAT3 activation in MESO-
1, H2452, MSTO-211H, and H28 cells, all of 
which show constitutive STAT3 activation (Fig. 
4A). Western blot analysis showed that treatment 
with BBI608 decreased phosphorylation of STAT3 
at Tyr705, without affecting the total STAT3 
level, in each mesothelioma cell line in a dose-
dependent manner after 4 h of treatment (Fig. 4A). 
As mentioned previously, STAT3 activated the 
transcription of a variety of genes responsible for 
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or 60 ng/mL) stimulated STAT3 phosphorylation in 
MESO-1, H2452, and H28 cells (Fig. 5A). MSTO-
211H cells did not respond to IL-6 stimulation at 
up to 100 ng/mL (data not shown). The induction 
of STAT3 phosphorylation by IL-6 was inhibited 
with BBI608 and the level of total STAT3 was not 
affected by treatment with BBI608 or IL-6 (Fig. 
5A). These results showed that BBI608 inhibited 
IL-6-induced STAT3 phosphorylation.
6. BBI608 suppressed secretion of IL-6.
   Because the IL-6 gene is under the control of 
STAT327）, we determined whether BBI608 blocked 
the secretion of IL-6. Basal IL-6 secretion levels in 
culture supernatants were determined by ELISA. 
Although all cell lines exhibited detectable basal 
production of IL-6 (15.3 ± 0.6 pg/mL in MESO-
1, 4.5 ± 1.0 pg/mL in H2452, 35.3 ± 2.8 pg/mL in 
Fig. 4. BBI608 suppressed constitutive STAT3 phosphorylation and induced tumor cell apoptosis.
(A) Dose-escalation effects of BBI608 on STAT3 phosphorylation at Tyr705. Mesothelioma cells were exposed 
to BBI608 at the indicated doses for 4 h, followed by harvesting of whole cell extracts. Protein levels were 
measured by western blotting. The level of STAT3 phosphorylation decreased in a dose-dependent manner. (B) 
Time-dependent analyses of the effects of BBI608 on phosphorylated STAT3 and STAT3 target proteins. Cells 
were exposed to 10 μM BBI608 for 4, 8, and 12 h. Treatment with the BBI608 downregulated cyclin D1 and 
decreased survival in all cells and downregulated Bcl-xL in some cells. BBI608 also induced cleavage of PARP, 
indicating apoptosis in the mesothelioma cell lines.
cell cycle regulation, anti-apoptotic effects, and 
other cancer hallmarks10）. In a time course study, we 
found that BBI608 suppressed the transcription of 
STAT3 downstream target proteins such as cyclin 
D1 and survivin in a time-dependent manner, but 
had minimal effect on Bcl-xL in many cells (Fig. 
4B). The level of phosphorylated STAT3 was 
upregulated in some cell lines after prolonged 
exposure (8-12 h) to BBI608. Our results also 
showed that BBI608 induced the cleavage of poly 
(ADP-ribose) polymerase (PARP), indicating 
apoptosis in mesothelioma cells.
5.  BBI608 suppressed IL-6-induced STAT3 
phosphorylation.
   IL-6  has been reported to induce STAT3 
phosphorylat ion and play a  role  in  cancer 
development26）. We found that exogenous IL-6 (40 
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H28, and 14.6 ± 0.8 pg/mL in MSTO-211H cells), 
the levels of IL-6  production varied widely 
depending on the cell type. After treatment with 
BBI608 for 4 h, the secretion of IL-6 was inhibited 
in MESO-1, H2452, and H28 cells, but in MSTO-
211H cells (Fig. 5B).
7. BBI608 suppressed nuclear translocation of 
STAT3.
   As a transcription factor, the translocation of 
STAT3 from the cytoplasm to the nucleus is 
important. To determine whether BBI608 affects 
STAT3 nuclear translocation, we performed an 
immunofluorescence assay. In cells at rest without 
IL-6 stimulation, the activated form of STAT3 was 
localized predominantly in the nucleus and BBI608 
suppressed nuclear translocation of phosphorylated 
STAT3  in all  cell lines (Fig. 6).  After IL-6 
stimulation in MESO-1, H2452, and H28 cells, the 
nuclear level of phosphorylated STAT3 increased 
and BBI608 suppressed this nuclear accumulation 
of phosphorylated STAT3 in stimulated cells 
(Fig. 6). IL-6 stimulation did not increase nuclear 
accumulation of phosphorylated STAT3 in MSTO-
211H cells (data not shown). Together, these results 
showed that BBI608 blocked STAT3 nuclear 
translocation. Furthermore, in mesothelioma 
cells responding to IL-6 stimulation, the nuclear 
accumulation of phosphorylated STAT3 by IL-6 was 
also blocked BBI608.
8. BBI608 suppressed the growth of H28 and 
MSTO-211H xenograft tumors.
   To examine the potential of using BBI608 as 
mesothelioma therapy, we next evaluated the 
inhibitory effect on tumor growth in vivo. H28 
and MSTO-211H xenograft models were created, 
although MESO-1 and H2452 xenograft models 
Fig. 5. BBI608 suppressed IL-6-induced phosphorylation of STAT3.
(A) BBI608 suppressed tyrosine phosphorylation of STAT3 induced by IL-6, without affecting the total STAT3 
protein level. MESO-1, H2452, and H28 cells were pretreated with different concentrations of BBI608 for 
4 h, followed by IL-6 stimulation (40 ng/mL for MESO-1 and H2452 cells and 60 ng/mL for H28 cells) for 
30 min, followed by harvesting of whole cell extracts. Protein levels were measured by western blotting. (B) 
BBI608 decreased the production of IL-6. Mesothelioma cells were treated with 10 μM BBI608 and the IL-6 
level in the culture supernatants was measured by ELISA. The data are expressed as means ± SEM of three 
independent experiments. *P < 0.05 compared with the control group.
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could not be generated despite multiple attempts. 
Following 21 days of BBI608 (40 mg/kg once per 
day) treatment, the tumor volumes and weights 
were estimated. BBI608 significantly suppressed 
tumor growth compared with the vehicle control 
group in H28 and MSTO-211H xenograft mice 
(Fig. 7A, B). The body weights of the mice in both 
groups showed no significant difference over the 
experimental period (Fig. 7C). IHC analyses showed 
decreased STAT3 phosphorylation and Ki-67 
expression, indicating the anti-proliferative effects 
of BBI608 (Fig. 8A). TUNEL assays showed that 
BBI608 induced tumor cell apoptosis in the mice 
(Fig. 8B).
Fig. 6. BBI608 suppressed STAT3 nuclear translocation.
Mesothelioma cells were starved overnight, followed by treatment with 10 μM BBI608 for 4 h. The cells were 
then treated with IL-6 (40 ng/mL for the MESO-1 and H2452 cells and 60 ng/mL for the H28 cells) for 30 min. 
Immunofluorescence was performed to determine the localization of phosphorylated STAT3 (red). Nuclei were 
stained with 4',6'-diamino-2-phenylindole (blue). BBI608 suppressed STAT3 nuclear translocation in all cells. 
In addition, IL-6 induced accumulation of phosphorylated STAT3 in the nuclei of MESO-1, H2452, and H28 
cells, whereas pretreatment with BBI608 blocked this process.
Fig. 7. BBI608 suppressed tumor growth in mouse xenografts.
(A, B) BBI608 significantly suppressed tumor volume and weight compared with the control group. After tumor 
development, the mice (n = 10) were randomized and intraperitoneally administered BBI608 (40 mg/kg once 
daily) or vehicle for 21 days, followed by detection of the tumor volume and weight. (C) The body weights of 
the mice in both groups did not significantly differ during the experimental period. The data are expressed as 
means ± SEM. *P < 0.05 and **P < 0.01 compared with the control group.
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DISCUSSION
   We demonstrated significant inhibitory effects 
by BBI608 on STAT3 phosphorylation, nuclear 
translocation, and transcriptional activity in 
mesothelioma cell lines. The inhibitors also showed 
significant antitumor activities in xenograft mouse 
models.
   Several genetic alterations and critical molecular 
s igna l ing  pa thways  have  been  iden t i f i ed 
as  contr ibut ing to  MPM development  and 
progression. These include the p53/DNA repair, 
cell cycle, mitogen-activated protein kinase, and 
phosphoinositide 3/AKT pathways and the immune-
checkpoint gene VISTA28，29）. Growing evidence 
has also shown that inflammatory signals from 
the surrounding microenvironment promote tumor 
growth and progression. In addition, inflammatory 
signaling has been associated with survival 
pathways and immunosuppression30）. It has been 
suggested that chronic inflammation due to asbestos 
exposure plays a critical role in the development and 
progression of MPM８）. The hallmarks of asbestos 
fiber inhalation include sustained inflammation, 
linked to the release of numerous cytokines, and 
generation of reactive oxygen species, which cause 
oxidative DNA damage31）. Several proinflammatory 
cytokines released by immune cells have been shown 
to promote cancer cell proliferation and progression, 
and increased expression of IL-6 is thought to 
act as a link between chronic inflammation and 
tumor development26）. In addition, IL-6/STAT3 
inflammatory cytokine signaling is a protumorigenic 
factor in breast, lung, colon, prostate, ovary, skin, 
and hematological malignancies30－32）. MPM has 
been reported to be an IL-6-secreting tumor16，33，34）. 
The increased expression of IL-6 in cancer cells 
suggests that IL-6 is an important autocrine growth 
factor that promotes tumorigenesis. Furthermore, 
activated STAT3 can also upregulate IL-6 induction 
via a positive IL-6 autocrine loop32）. Adachi et 
Fig. 8. Inhibitory effects of BBI608 in vivo
Tumor sections were analyzed by immunohistochemistry for detection of STAT3 phosphorylation at Tyr705 
and the proliferation marker Ki67. Apoptotic cells were determined by TUNEL assay and propidium iodide 
staining (red). TUNEL-positive apoptotic cells were detected by localized FITC fluorescence (green). Tumors 
were harvested after 21 days of BBI608 or vehicle treatment. (A) BBI608 significantly suppressed STAT3 
phosphorylation and tumor proliferation (magnification, 200×; scale bars, 100 μm). (B) TUNEL assays 
showed that BBI608 induced apoptosis in vivo (magnification, 200×). The percentage of positive cells in each 
group was counted, and the cumulative data from three independent experiments are expressed as means ± 
SEM. *P < 0.05 and **P < 0.01 compared with the control group.
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al. reported that IL-6, in an autocrine manner, is 
involved in MPM growth via STAT3 signaling17）. 
One of the most important downstream target genes 
of IL-6 is STAT3, which is constitutively activated 
in various types of cancers, including mesothelioma. 
IL-6 induces STAT3 phosphorylation at Tyr705 via 
the JAK pathway35）. We found no altered activity 
of JAK1 or JAK2, which are not phosphorylated in 
MESO-1, H2452, H28, or MSTO-211H cells, after 
treatment with BBI608 (data not shown).
   STAT3 activation results in the expression 
of  downstream targets ,  such as cyclin D1 , 
survivin, Bcl-xl, and Bcl-210）, which promote 
cell proliferation and resistance to apoptosis35）. 
Numerous novel molecular inhibitors of STAT3, 
such as BBI608, LLL12, and LY5, have been 
reported to suppress cancer cells and tumor 
growth21，36，37）. Although the function of IL-6 has 
been investigated extensively, little is known about 
the biological function of STAT3 in MPM. Among 
novel STAT3 inhibitors, BBI608 is well examined 
in the patients with refractory advanced colorectal 
cancer as a phase 3 study. In the patients harboring 
phosphorylated STAT3 in the tumor, overall survival 
was longer in the BBI608 group than in the placebo 
group, although there was no difference in overall 
survival between groups in the overall unselected 
population38）. We therefore investigated whether 
STAT3 is a druggable target in MPM cells. BBI608 
blocked constitutive STAT3 phosphorylation 
in all cell lines, as well as IL-6-induced STAT3 
phosphorylation in MESO-1, H2452, and H28 
cells. The effects of BBI608 on STAT3 downstream 
target proteins included decreased cell viability 
and increased apoptosis with cell cycle arrest. 
The immunostaining results showed that BBI608 
effectively inhibited phosphorylation of STAT3 in 
the nucleus. We found that both IL-6 production and 
STAT3 phosphorylation were suppressed in most 
cells treated with BBI608.
   Concerning the toxicity of BBI608, the body 
weights of the mice treated with the drug and with 
vehicle were similar (Fig. 7C). In the phase 3 study 
comparing BBI608 to placebo in the patients with 
colorectal cancer, more patients who received 
BBI608 had any grade of treatment-related diarrhea 
(79% vs 19%), nausea (51% vs 24%), and anorexia 
(38% vs 16%) than did patients who received 
placebo38）. Grade 3 or worse adverse events of 
BBI608 and placebo were abdominal pain (4% vs 
3%), diarrhea (15% vs 1%), fatigue (10% vs 6%), 
and dehydration (4% vs 1%). Thus, adverse events 
of BBI608 were generally mild.
   In conclusion, BBI606 was effective in our 
preclinical MPM models and might suppress the 
IL-6/STAT3 signaling axis by reducing autocrine 
IL-6 production. Further studies are required to 
elucidate other mechanisms such as blocking cancer 
stemness39）.
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